10 months before production and sales of instrumentation
According to statistics from the China Machinery Industry Federation, in the first 10 months of this year, except for the year-on-year growth rate of the internal combustion engine industry in the machinery industry, the growth rate of most industries was slightly higher than that of the previous month. From January to October, most industries in the machinery industry saw a growth trend, and the instrumentation industry increased by 16.50% year-on-year. In terms of main business income, the cumulative growth rate of six of the six industries exceeded or remained the industry average. The three industries with the fastest year-on-year growth were the agricultural machinery industry, the instrumentation industry, and the petrochemical industry, with growth rates of 14.8%, 14.61%, and 14.03%, respectively. Among the 120 main products of China National Computer Federation’s statistics, there are 69 kinds of products that have accumulated year-on-year growth, accounting for 57.5% of all reported product varieties; of these products, 46 products have grown by double digits, accounting for 38.33 of all reported products. %; There are 50 kinds of products produced less than last year, accounting for 41.67% of the reported products.
Apart from the decrease of 3.58% year-on-year in analytical instruments and devices, the output of other products showed a different degree of growth, among which optical instruments grew rapidly and grew by 23.26% year-on-year. Industrial automation instrumentation and control systems, automotive instrumentation and special instrumentation for environmental monitoring showed steady growth, with year-on-year growth rates above 8%.
Gilteritinib is an orally bioavailable inhibitor of the receptor tyrosine kinases (RTKs) FMS-related tyrosine kinase 3 (FLT3, STK1, or FLK2), AXL (UFO or JTK11) and anaplastic lymphoma kinase (ALK or CD246), with potential antineoplastic activity. Gilteritinib binds to and inhibits both the wild-type and mutated forms of FLT3, AXL and ALK. This may result in an inhibition of FLT3, AXL, and ALK-mediated signal transduction pathways and reduces tumor cell proliferation in cancer cell types that overexpress these RTKs. FLT3, AXL and ALK, overexpressed or mutated in a variety of cancer cell types, play a key role in tumor cell growth and survival.
Gilteritinib is an orally available small molecule inhibitor of FMS-like tyrosine kinase 3 (FLT3) which is used as an antineoplastic agent in the treatment of acute myeloid leukemia with FLT3 mutations. Gilteritinib is associated with a moderate rate of serum aminotransferase elevations during therapy and is suspected to cause rare instances of clinically apparent acute liver injury.
Gilteritinib is a member of the class of pyrazines that is pyrazine-2-carboxamide which is substituted by {3-methoxy-4-[4-(4-methylpiperazin-1-yl)piperidin-1-yl]phenyl}nitrilo, (oxan-4-yl)nitrilo and ethyl groups at positions 3,5 and 6, respectively. It is a potent inhibitor of FLT3 and AXL tyrosine kinase receptors (IC50 = 0.29 nM and 0.73 nM, respectively). Approved by the FDA for the treatment of acute myeloid leukemia in patients who have a FLT3 gene mutation. It has a role as an apoptosis inducer, an EC 2.7.10.1 (receptor protein-tyrosine kinase) inhibitor and an antineoplastic agent. It is a N-methylpiperazine, a member of piperidines, a secondary amino compound, a monomethoxybenzene, a member of pyrazines, a primary carboxamide, an aromatic amine and a member of oxanes.
Gilteritinib Api,Gilteritinib Cas 1254053-43-4,Gilteritinib Asp2215 2 Pyrazinecarboxamide,Gilteritinib Api Cas 1254053-43-4
 Shandong Haohong Biotechnology Co., Ltd. , https://www.haohongpharma.com